BC Week In Review | Jan 11, 2016
Clinical News

GNbAC1: Phase IIb started

GeNeuro began the placebo-controlled, European Phase IIb CHANGE-MS trial to evaluate GNbAC1 in 260 patients. In 2014, GeNeuro granted Servier (Neuilly-sur-Seine, France) an option to license exclusive rights to develop and commercialize GNbAC1 worldwide, excluding...
BC Innovations | Jun 11, 2015
Targets & Mechanisms

GeNeuro goes retro

GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro...
BioCentury | Dec 8, 2014
Product Development

Verve for HERV

Servier could make its first foray into multiple sclerosis via an option deal with GeNeuro S.A. that it hopes will yield the first therapy targeted at a cause of the disease. Last week Servier agreed...
BioCentury | Feb 19, 2007
Emerging Company Profile

GeNeuro: Unraveling secrets of HERV

GeNeuro S.A. thinks its work on human endogenous retroviruses may have uncovered the cause of neurodegenerative diseases like multiple sclerosis and as a result may offer a new therapeutic strategy. The company has an antibody...
Items per page:
1 - 4 of 4